News

XTANDI™ Breakthrough: Prostate Cancer Patients See 30% Survival Increase

XTANDI™ Breakthrough: Prostate Cancer Patients See 30% Survival Increase

Long-term Survival Benefits of XTANDI™ in Prostate Cancer

Recent follow-up data from the Phase 3 ARCHES trial has showcased remarkable findings regarding XTANDI™ (enzalutamide) in the treatment of metastatic hormone-sensitive prostate cancer. XTANDI, combined with androgen deprivation therapy (ADT), has demonstrated a 30% reduction in the risk of death, indicating its significant role in modern prostate cancer treatment.

Impressive Five-Year Survival Rates

An in-depth examination over a median follow-up period of 61.4 months revealed that patients receiving XTANDI in conjunction with ADT had a 66% probability of survival after five years. In comparison, those on placebo plus ADT showed only a 53% survival probability. This makes XTANDI the first and only androgen receptor inhibitor to exhibit a notable overall survival benefit at this five-year mark for men suffering from this type of cancer.

Impact Across Patient Subgroups

The ARCHES trial highlighted the treatment's efficacy across various subgroups of patients, including those with high-volume disease and those who had not received docetaxel prior to therapy. The long-term data reinforces the position of XTANDI plus ADT as a standard treatment regimen for managing metastatic prostate cancer, making it a critical option for patients navigating this challenging diagnosis.

Expert Insights on XTANDI’s Efficacy

Oncologists have noted a significant shift in survival rates due to treatments like XTANDI. Dr. Andrew J. Armstrong, an expert in prostate cancer research, described the improved outcomes, stating that two-thirds of men are now surviving five years post-treatment—a 13% absolute and 30% relative improvement over conventional hormonal therapies. This kind of advancement is monumental in the journey to enhance patient outcomes.

Consistent Survival Benefits

The follow-up study also highlighted consistent survival benefits in various clinically relevant subgroups. Patients with high-volume disease experienced a median overall survival improvement of 36 months, reinforcing the broad applicability and effectiveness of XTANDI across cancer stages and patient histories.

Longitudinal Studies Support Treatment Standards

Data from the extended ARCHES study will be submitted for future publication, marking another stride toward understanding the long-term impacts of XTANDI in clinical settings. Dr. Shontelle Dodson from Astellas emphasized how the growing body of evidence continues to confirm XTANDI’s long-term efficacy, showcasing a transformative impact on patients' lives.

A Broader Landscape of Evidence

In addition to the five-year findings from the ARCHES trial, the ENZAMET trial has also revealed positive outcomes regarding enzalutamide. This study, which compares enzalutamide's performance against non-steroidal anti-androgen therapies, is set to present its eight-year data, providing comprehensive insights into the sustainability of XTANDI's benefits over time.

Current Approvals and Worldwide Impact

XTANDI has received regulatory approval in over 90 countries, securing its place as a front-line treatment for patients with metastatic hormone-sensitive prostate cancer. Over one million patients have benefitted from XTANDI globally since its launch in 2012, highlighting its extensive use and trust within the medical community.

Understanding Metastatic Hormone-Sensitive Prostate Cancer

Metastatic hormone-sensitive prostate cancer occurs when cancer spreads beyond the prostate gland, yet remains responsive to hormonal therapy. The data emerging from recent studies underscores the pivotal role of targeted therapies like XTANDI in managing this challenging condition effectively, heralding a new era in prostate cancer care.

Frequently Asked Questions

What is XTANDI™?

XTANDI™ (enzalutamide) is an androgen receptor signaling inhibitor used to treat advanced prostate cancer, exhibiting significant survival benefits.

How does XTANDI™ work?

XTANDI works by inhibiting the androgen receptor pathway, reducing cancer growth and improving patient survival rates in advanced prostate cancer cases.

What were the key findings of the ARCHES trial?

The ARCHES trial indicated a 30% reduction in death risk and higher survival probabilities for patients receiving XTANDI™ compared to placebo.

Is XTANDI™ widely available?

Yes, XTANDI is approved in over 90 countries, making it a widely accessible treatment for prostate cancer patients.

What are the side effects of XTANDI™?

Common side effects include fatigue, musculoskeletal pain, and hot flushes, with monitoring for more serious conditions required.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Melio’s AP Push Looks Useful, but Read the Fine Print

Updated Category News Views 73

Back-office drudgery rarely gets anyone’s pulse racing, yet it can quietly chew through a small business’s time and cash. That is why Melio’s latest recognition as Software Experts’ top pick for accounts payable automation deserves a look. The product pitch is straightforward: pull bills, approvals, payments and reconciliation into one workflow rather than leaving...

Continue Reading
Illumina's Virtual Cell Win Raises Bigger AI Stakes

Updated Category News Views 70

A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 56

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 111

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 22

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 165

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 0

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 170

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 130

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Collaboration in Nuclear Electric Propulsion

Updated Category News Views 179

Exciting Advances in Nuclear Electric Propulsion Space Nuclear Power Corporation has embarked on a groundbreaking partnership with the United States Space Force (USSF) and the Space Strategic Technology Institute hosted by a prominent Michigan university. This collaboration aims to develop advanced nuclear electric propulsion systems designed for future space missions....

Continue Reading
Dali's Global Ecological Forum: A Step Towards Greener Futures

Updated Category News Views 81

Dali's Ecological Achievements Take Center Stage Dali, a picturesque city in Yunnan, China, has become a beacon of ecological progress, recently showcasing its achievements at the 2024 Erhai Forum on Global Ecological Civilization Construction. With a theme centered on 'Working Together to Promote Eco-Friendly Modernization', this important event took place in October and...

Continue Reading
Opportunity for Investors to Lead Wolfspeed Securities Case

Updated Category News Views 301

Update for Investors of Wolfspeed, Inc. Wolfspeed, Inc. (NYSE: WOLF) has become the center of attention as investors seek justice after experiencing significant losses. Those who have purchased securities between specific dates are being invited to take action regarding a potential case of securities fraud. Understanding the Class Action Opportunity The Rosen Law Firm, a...

Continue Reading
Updates from Schouw & Co.'s Share Buy-Back Programme Progress

Updated Category News Views 115

Overview of Schouw & Co. Share Buy-Back Programme On May 5, Schouw & Co. took a significant step in enhancing shareholder value by launching a share buy-back programme. As outlined in their company announcement from May 2, the initiative allows for the acquisition of shares valued up to DKK 120 million. The duration of this programme extends from May 5 to December 31....

Continue Reading
Academy Sports Expands Across Multiple States with New Stores

Updated Category News Views 213

Academy Sports and Outdoors Expands Its Reach Academy Sports and Outdoors, Inc. (NASDAQ: ASO) is executing an ambitious plan to bolster its presence through multi-state expansion. This entails the opening of new store locations while nurturing community partnerships aimed at enhancing value for shoppers. Recent Store Openings Recently, the retailer has launched new...

Continue Reading